Skip to main content
Caplight Logo









IPRASENSE

IPRASENSE

Private
ClapiersHealthcare & Life Scienceshttps://www.iprasense.com/

Last Round

Grant

Nov 1, 2021

Total Funding Raised

$1.89M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

IPRASENSE is a life sciences company that develops and commercializes innovative cell culture monitoring equipment, including automated cell counters and viability analyzers.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Medical Devices, Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Services & Consulting

AI Layer

Application

Keywords

cell culture monitoringlive-cell imagingautomated cell counterlabel-free imaginglensless imagingdigital holographic microscopycell viability analysisholographic imagingbioprocess controlhigh-throughput screeningprocess analytical technologyPATbiotech equipmentdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

IPRASENSE Comparables

Compare IPRASENSE with similar companies based on industry and business-model similarity.

IPRASENSE comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Phase Holographic Imaging AB
81%
Aligned Genetics
79%
Nanolive SA
77%

IPRASENSE Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 1, 2021
AcceleratorJul 1, 2019
GrantMay 1, 2018

IPRASENSE Investors

Notable investors and investment history

IPRASENSE investors
InvestorRounds
Innovative Health InitiativeGrant
European CommissionGrant
SATT AxLRAccelerator
BpifranceGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased from 0 to 2, representing 67% of headcount.

  • Jul 2, 2025

    Monthly visitors increased 49% MoM.

IPRASENSE Filings

Explore SEC and related filing metadata, where available.

IPRASENSE filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about IPRASENSE's valuation, stock price, and market status.

Is IPRASENSE a public or private company?

IPRASENSE is a private company.

What is the current stock price of IPRASENSE?

IPRASENSE is a private company with no public stock price. No recent secondary market data is available.

How much is IPRASENSE worth (valuation)?

Valuation information for IPRASENSE is not publicly available.

Can I buy IPRASENSE stock?

IPRASENSE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was IPRASENSE's last funding round?

IPRASENSE's most recent funding round was Grant on November 1, 2021.

Who are the main investors in IPRASENSE?

Key investors in IPRASENSE include Innovative Medicines Initiative 2 Joint Undertaking, SATT AxLR, Bpifrance.

Will IPRASENSE IPO soon?

No public IPO plans have been announced for IPRASENSE.

How can I track IPRASENSE secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor IPRASENSE's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersClapiers
Employee Range4
Year Founded2013
Last FundingNov 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?